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BACKGROUND: Establishment of inexpensive clinical laboratory tests to evaluate inflammation and oxidative stress is urgently needed in the 
limited resources settings. This study aims to investigate 
the potential of complete blood count (CBC) parameters 
and non-fasting cholesterol profile parameters to describe 
inflammation and oxidative stress in chronic kidney disease 
(CKD) patients.
METHODS: Measurement of CBC, non-fasting 
cholesterol profile, high sensitivity C-reactive protein 
(hs-CRP) and malondialdehyde (MDA) were performed 
in 71 CKD patients grouped into hemodialysis (HD) and 
non-hemodialysis (non-HD). Correlation analysis were 
performed to assess the potential of CBC and cholesterol 
profile to describe the level of hs-CRP and MDA.
RESULTS: In the HD group, total cholesterol was 
moderately associated with hs-CRP while total cholesterol/
HDL-C ratio, monocyte/HDL-C ratio, monocyte/LDL-C 
ratio, neutrophil/HDL-C ratio, neutrophil/LDL-C ratio, 
platelet/HDL-C ratio and platelet/LDL-C ratio were 
strongly associated with hs-CRP.  In the non-HD group, 
only neutrophil/total cholesterol ratio and platelet/total 
cholesterol ratio that were associated with hs-CRP. Total 
cholesterol, monocyte/LDL-C ratio, neutrophil/LDL-C 
ratio and platelet/LDL-C ratio were moderately associated 
with MDA while total cholesterol/HDL-C ratio, monocyte/
HDL-C ratio, neutrophil/HDL-C ratio and platelet/HDL-C 
ratio were strongly associated respectively with MDA in 
HD group. In the non-HD group, total cholesterol/HDL-C 
ratio, neutrophil/HDL-C ratio and platelet/HDL-C ratio 
were moderately associated with MDA in non-HD group 
while monocyte/HDL-C ratio was weakly associated with 
MDA.
CONCLUSION: Some CBC parameters and non-fasting 
cholesterol profile such as cholesterol/HDL-C, monocyte/
HDL-C, neutrophil/HDL-C and platelet/HDL-C ratio were 
strongly associated with the level of hs-CRP and MDA. 
Further study with higher number of subjects is needed to 
assess whether this parameter represent prognostic value 
among CKD patients.
KEywORDS: inflammation, oxidative stress, CRP, MDA, 
TAC, 8-OHdG, CBC, cholesterol
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Cardiovascular disease (CVD) is the major contributor of 
mortality in chronic kidney disease (CKD).(1) Mortality due 
to CVD in CKD patients is 10- to 20-fold  higher compare to 
general population.(1) Continuous assessment of CVD risk 
factor is helpful to guide modification of therapy to prevent 
CVD in CKD patients. 
 Inflammation  and  oxidative  stress  appear  to 
increase as CKD progresses and play pivotal roles in the 
pathogenesis and progression of CKD.(2) These two 
factors are regarded as non-traditional risk factors that 
highly contributed to the development of CVD in patients 
with CKD.(2) Inflammation and oxidative stress are also 
associated with higher mortality in patients receiving 
long-term hemodialysis therapy.(3) Therefore, continuous 
assessment of inflammation and oxidative stress will be 
useful to predict CVD risk in the CKD patients.
 High sensitivity C-reactive protein (hs-CRP) is one of 
the most widespread inflammatory biomarkers commonly 
used for clinical purposes since it has several advantages 
such as good chemical stability and long half-life without 
diurnal variation.(4) Malondialdehyde (MDA), a marker 
of lipid oxidation on erythrocyte surface, is a biomarker 
to assess oxidative stress in CKD patients.(5) The hs-CRP 
and MDA are commonly used in developed countries to 
evaluate inflammation and oxidative stress.(5) However, 
in the developing countries, continuous evaluation of 
inflammation and oxidative stress of CKD patients through 
hs-CRP and MDA is still difficult.(6) Unfortunately, there 
are no established routine affordable clinical laboratory tests 
that could be used to evaluate inflammation and oxidative 
stress in CKD patients.
 Previous studies showed that ratio of neutrophil to 
lymphocytes, two parameters in the complete blood count 
(CBC) test, could be used to predict inflammation in several 
diseases.(7,8) Refunctioning routine laboratory test to 
evaluate inflammation and oxidative stress will help health 
provider in health center with limited facilities to perform 
uninterrupted continuous assessments of CVD risk in CKD 
patients in a more feasible way. CBC test and non-fasting 
cholesterol profile were two kinds of routine laboratory 
test that could be perform in almost all health center with 
relatively affordable cost. In addition, these tests could be 
done in patients without any preparations such as 10 hours 
of fasting. So, these kind of clinical laboratory tests could 
be performed in CKD patients with small limitations. 
Methods
Study Design and Population Selection
Participants for this cross-sectional study were recruited 
consecutively from outpatient clinics and hemodialysis 
units of government and private hospitals in Surabaya and 
Makassar, Indonesia, from March until August 2017. The 
number of samples required for this study was calculated 
based on a of 0.05, b of 0.2 and expected correlation 
coefficient (r) of 0.5 for non-hemodialysis (non-HD) group 
and r of 0.6 for hemodialysis (HD) group.(9) The expected 
correlation coefficient was calculated based on previous 
study.(7,8,10) For this study, a total of 71 patients that ≥ 
21-year-old with diagnosis of CKD were recruited. The 
diagnosis of CKD was confirmed by The National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative 
(NKF K-DOQI) criteria based on CKD epidemiology 
collaboration (CKD-EPI) equation (estimated glomerular 
filtration rate (eGFR) ≤ 60 mL/min/1,73m2; urine albumin, 
albumin to creatinine ratio).(11) Exclusion criteria included 
overt infection, fever in the last 3 days, signs of infection, 
acute inflammatory disease, and malignancy. The study 
protocol was approved by Ethics Committee of Universitas 
Airlangga hospital Surabaya, Indonesia (Reference No. 
093/IGH/2017). 
 Study participants underwent a detailed review of 
their disease history, physical examinations, and laboratory 
measurements at the time of enrollment. Subjects were 
classified based on their hemodialysis status. Subjects who 
received routine hemodialysis treatment were belong to HD 
group, while subjects who did not received any hemodialysis 
treatment were belong to non-HD group. Since we expected 
a higher correlation coefficient in the HD group, the number 
of required samples in the HD group was fewer than in the 
non-HD group. 
Laboratory Measurements
Participants underwent blood and urine sampling early 
in the morning. Serum creatinine, serum cystatin-C 
and hemoglobin A1c (HbA1c) were measured based on 
established laboratory method previously explained.(12) 
Introduction Therefore, this study aims to investigate the associations between hs-CRP and MDA as established biomarkers of 
inflammation  and  oxidative  stress  with  CBC  and  non-
fasting cholesterol profile that are routinely tested in CKD 
patients. 
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CBC and non-fasting cholesterol profile (total cholesterol, 
high density lipoprotein cholesterol (HDL-C), low density 
lipoprotein cholesterol (LDL-C)) were measured from 
blood sample of the patients based on established laboratory 
method previously explained (REF). The hs-CRP was used as 
an inflammatory biomarker. hs-CRP was measured in blood 
using particle enhanced turbidimetry (Rohce Diagnostic, 
CA, USA). MDA was used as biomarker of oxidative stress. 
MDA was measured in the blood serum process by high-
performance liquid chromatography (HPLC) method using 
Agilent 1100. All of the laboratory measurements were done 
in the good laboratory practice certified laboratory.
Statistical Analysis
 The quantitative data was analyzed using Saphiro-
Wilk for normality test. For normally distributed variables, 
data were shown as mean±SD. For skewed variables, data 
were shown as median and interquartile range (1st quartile 
- 3rd quartile). To investigate the differences between f 
two groups, Student's T-test was used if data had normal 
distribution and Mann-Whitney U-test was used in case 
of data with non-normal distribution. Chi-square test was 
used to evaluate the difference between categorical data of 
two group. Correlation between variables was performed 
using Pearson correlation test. All tests were two-tailed 
with significance level of 0.05. The statistical analyses 
were performed  using  XLSTAT  software  version 
2016.02.28451.
Results
Characteristics of the Study Participants
Characteristics of the study participants based on 
hemodialysis status were shown in the Table 1. As expected, 
kidney function parameters were significantly better in No-
HD than in HD group (p<0.0001 for eGFR, urine ACR, 
serum creatinine, and serum cystatin-C), while the number 
of erythrocytes (p=0.006) was significantly lower in the 
HD than in non-HD group. Regarding to the CVD risk 
factors, HD group showed more CVD risk factors compare 
to non-HD since it had significantly higher blood pressure 
both systolic blood pressure (p<0.0001) and diastolic blood 
pressure (p=0.016), higher inflammation as shown by higher 
level of hs-CRP (p=0.010) and also higher level of oxidative 
stress as shown by higher level of serum MDA (p<0.0001). 
However, cholesterol profile of HD group showed 
significantly lower level of total cholesterol (p=0.013) and 
LDL-C (p=0.037) compare to non-HD.
Combination of Blood Count Parameters and Non-
fasting Cholesterol Profiles are Highly Associated with 
hs-CRP
In order to investigate the relationship between CBC 
parameters, cholesterol profile, and hs-CRP as an established 
marker of inflammation, we performed correlation tests 
between each single or combination of CBC parameters 
with hs-CRP. However, there is no single CBC parameters 
or combination CBC parameters that was associated with 
hs-CRP (data not shown).
 Then, we performed correlation tests between each 
single parameters or combination of cholesterol profile 
parameters with hs-CRP. Total cholesterol (p=0.008, 
r=0.547) and total cholesterol/HDL-C ratio (p<0.0001, 
r=0.733) were moderately and strongly associated 
respectively with hs-CRP in the HD group as shown in the 
Table 2.
 Next, we performed correlation tests between 
combination of CBC parameters and cholesterol profile 
parameters with hs-CRP. In HD group, combination 
between monocyte or neutrophil or platelet and HDL-C 
or LDL-C (monocyte/HDL-C ratio (p<0.0001, r=0.776), 
monocyte/LDL-C ratio (p<0.0001, r=0.798), neutrophil/
HDL-C ratio (p<0.0001, r=0.757), neutrophil/LDL-C ratio 
(p<0.0001, r=0.771), platelet/HDL-C ratio (p<0.0001, 
r=0.761) and platelet/LDL-C ratio (p<0.0001, r=0.801)) 
were strongly associated with hs-CRP while in the non-HD, 
only neutrophil/total cholesterol ratio (p=0.006, r=0.404) 
and platelet/total cholesterol ratio (p=0.008, r=0.392) that 
were associated with hs-CRP.
Combination of CBC Parameters and Non-fasting 
Cholesterol Profiles are Highly Associated with Serum 
MDA
To evaluate the relationship between complete blood 
count parameters, cholesterol profile, and serum MDA, as 
an established marker of oxidative stress, we performed 
correlation tests between each single or combination of 
CBC parameters with MDA. However, there is no single 
CBC parameters or combination CBC parameters that was 
associated with MDA (data not shown).
 Then, we performed correlation tests between each 
single parameters or combination of cholesterol profile 
parameters with MDA. Total cholesterol (p<0.0001, r=0.690) 
and total cholesterol/HDL-C ratio (p<0.0001, r=0.784) were 
moderately and strongly associated respectively with MDA 
in HD group as shown in the Table 3. Total cholesterol/
HDL-C ratio (p<0.0001, r=0.570) was also moderately 
associated with MDA in non-HD group.
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Discussion
CVD is the leading cause of mortality in CKD.(2)
Inflammation and oxidative stress are regarded as non-
traditional risk factors that highly contributed to the 





57.62 ± 10.98 58.13 ± 5.92 NS
12/14 18/27 NS
eGFR (mL/minute/1.73 m2) 3 (2-4) 29 (22-60) 0.000*
Urine ACR (mg/g) 1789 (834-3473) 184 (18-803) 0.000*
Serum Creatinine (mg/dL) 14.14 (11.51-15.95) 1.88 (1.29-2.59) 0.000*
Serum Cystatin-C (mg/L) 7.42 (6.58-7.94) 1.88 (1.28-2.61) 0.000*
Leukocytes (109/L) 7.95 (6.50-9.45) 7.80 (7.00-9.90) NS
Neutrophil (109/L) 5.10 (4.01-6.74) 4.80 (4.19-5.82) NS
Lymphocytes (109/L) 1.48 (1.16-1.62) 1.85 (1.56-2.39) 0.000*
Eosinophil (109/L) 0.33 (0.24-0.47) 0.23 (0.16-0.41) 0.034*
Basophil (109/L) 0.050 (0.03-0.07) 0.051 (0.03-0.06) NS
Monocytes (109/L) 0.47 (0.36-0.59) 0.49 (0.35-0.54) NS
Erythrocytes (106/cm3)+ 3.90 ± 0.49 4.34 ± 0.69 0.006*
Hemoglobin (g/dL) 11.41 ± 1.48 12.10 ± 1.77 NS
Platelets (103/mm3)+ 233.23 ± 59.61 248.13 ± 73.08 0.004*
Hematocrit (%) 35.94 ± 4.60 37.28 ± 5.41 NS
HbA1c (%) 6.15 (5.52-6.85) 6.90 (6.00-8.30) 0.028*
Systolic Blood Pressure (mmHg) 156 (143-167) 126 (112-132) 0.000*
Diastolic Blood Pressure (mmHg)+ 82 ± 9 75 ± 13 0.016*
Total Cholesterol (mg/dL) 189 (151-206) 215 (182-245) 0.013*
HDL Cholesterol (mg/dL)+ 39 ± 13 44 ± 15 NS
LDL Cholesterol (mg/dL) 107 (83-126) 130 (101-155) 0.037*
hs-CRP 2.10 (1.65-8.05) 1.40 (0.90-3.20) 0.010*
Serum MDA (mmol/L) 3.15 (2.82-3.69) 2.37 (2.16-2.67) 0.000*





Complete Blood Count 
Table 1. Characteristics of the dialysis and pre-dialysis subjects.
Data are expressed in Mean ± SD+ or Median (Interquartile range). eGFR: estimated glomerular 
filtration rate; ACR: Albumin to creatinine ratio; HbA1c: Hemoglobin A1c; hs-CRP: High 
sensitivity C-reactive protein; HDL-C: High density lipoprotein cholesterol; LDL-C: Low 
density lipoprotein cholesterol; MDA: Malondialdehyde; NS: Not significant. *p<0.05 was 
considered significant.
 Next, we performed correlation tests between 
combination of CBC parameters and cholesterol profile 
parameters with CRP. In HD group, combination between 
monocyte or neutrophil or platelet and HDL-C (monocyte/
HDL-C ratio (p<0.0001, r=0.766), neutrophil/HDL-C ratio 
(p<0.0001, r=0.753) and platelet/HDL-C ratio (p<0.0001, 
r=0.766) were strongly associated with MDA while 
combination between monocyte or neutrophil or platelet 
and LDL-C (monocyte/LDL-C ratio (p=0.003, r=0.606), 
neutrophil/LDL-C ratio (p=0.005, r=0.578) and platelet/
LDL-C ratio (p=0.001, r=0.655) were moderately associated 
with MDA. In non-HD group, combination between 
monocyte or neutrophil or platelet and HDL-C (monocyte/
HDL-C ratio (p=0.002, r=0.459), neutrophil/HDL-C ratio 
(p<0.0001, r=0.532) and platelet/HDL-C ratio (p<0.0001, 
r=0.594) were associated with MDA.
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Table 2. Correlation between combination of blood counts and cholesterol profile 
with CRP among subjects of HD and non-HD group.
r p- value r p- value
Total cholesterol 0.547 0.008* -0.036 0.812
Total cholesterol/HDL-C 0.733 0.000* 0.05 0.746
Monocyte/HDL-C 0.776 0.000* 0.278 0.064
Monocyte/LDL-C 0.798 0.000* 0.191 0.208
Monocyte/Total cholesterol 0.176 0.434 0.213 0.160
Neutrophil/HDL-C 0.757 0.000* 0.247 0.101
Neutrophil/LDL-C 0.771 0.000* 0.254 0.092
Neutrophil/Total cholesterol 0.205 0.360 0.404 0.006*
Platelet/HDL-C 0.761 0.000* 0.154 0.314
Platelet/LDL-C 0.801 0.000* 0.223 0.141




HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein 
cholesterol. *p<0.05 was considered significant.
r p- value r p- value
Total cholesterol 0.69 0.000* 313 0.036*
Total cholesterol/HDL-C 0.784 0.000* 0.57 0.000*
Monocytes/HDL-C 0.766 0.000* 0.459 0.002*
Monocytes/LDL-C 0.606 0.003* -0.091 0.554
Monocytes/Total cholesterol 0.246 0.270 0.247 0.102
Neutrophil/HDL-C 0.753 0.000* 0.532 0.000*
Neutrophil/LDL-C 0.578 0.005* 0.077 0.616
Neutrophil/Total cholesterol -0.184 0.413 -0.121 0.428
Platelets/HDL-C 0.766 0.000* 0.594 0.000*
Platelets/LDL-C 0.655 0.001* 0.342 0.021*
Platelets/Total cholesterol -0.335 0.128 0.157 0.302
Variable
Serum MDA
     HD      Non-HD
HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol. 
*p<0.05 was considered significant.
Table 3. Correlation between combination of blood counts and cholesterol profile 
with serum MDA among subjects of HD and non-HD group.
Continuous assessment of inflammation and oxidative stress 
through hs-CRP and MDA is useful to predict CVD risk 
in the CKD patients.(14,15) Unfortunately, assessment of 
these two commonly used biomarkers for inflammation and 
oxidative stress in developed countries is infeasible in most 
developing countries with limited resources and facilities.
(6) Establishment of inexpensive clinical laboratory tests 
that could be used to evaluate inflammation and oxidative 
stress is urgently needed in the area with limited resources 
and facilities.
 Several studies showed the potential of using routine 
laboratory tests to become surrogate marker for inflammation 
in wide range of diseases, including CKD.(7,8,10) Previous 
study recommended neutrophil/lymphocyte ratio (NLR) 
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to become surrogate marker of systemic inflammation in 
dialysis patients.(16) Other study suggested that NLR could 
be used to provide information related to inflammatory 
condition in both HD and non-HD CKD patients.(17) 
Platelet/lymphocyte ratio (PLR) was suggested by 
other study to become a superior surrogate marker of 
inflammation in stage 5 CKD compare to NLR.(18) Instead 
of looking for new inexpensive biomarkers, these studies 
suggested the potential reutilizing of established routine 
clinical laboratory tests such as CBC to become surrogate 
markers for inflammation in CKD. Therefore, in this study, 
we investigated the potential of CBC parameters and 
cholesterol profile parameters to become surrogate markers 
for inflammation and oxidative stress in CKD patients, both 
in HD and non-HD.
 Regarding to the cholesterol profiles, instead of 
using fasting cholesterol profiles, we measured non-
fasting cholesterol profiles. Although fasting cholesterol 
profiles is measurement that used conventionally, a recent 
consensus from European Federation of Clinical Chemistry 
and Laboratory Medicine, the European Atherosclerosis 
Society, the British National Clinical guideline and the new 
Canadian guideline recommends that fasting is not routinely 
required for cholesterol profile measurement.(19-21) The 
non-fasting measurement of cholesterol profiles has some 
benefits such as providing easier and simpler procedure for 
patients since patients are able to eat normally. Since this 
test could be performed any time regardless the time, it may 
prevent long waiting times for patients. This test condition 
also allows health providers to determine the cholesterol 
profiles at random moment. Large scale studies showed that 
cholesterol profile is only minimally affected after habitual 
food intake.(19,22,23)
 Since inflammation and oxidative stress appears to 
increase along with the advancement of CKD (24), in this 
cross-sectional study, participants were classified into two 
groups based on their hemodialysis status. This previous 
result was concordance with result of our study. In our 
study, HD group showed higher inflammation and oxidative 
stress compare to non-HD group as shown by higher level 
of hs-CRP and MDA. 
 This study showed that HD patients exhibited higher 
hs-CRP and MDA level. This confirmed the finding of 
numerous study demonstrating the additional inflammation 
and oxidative stress burden in HD compared to non-HD 
patients. The mechanism of inflammatory states in CKD 
patients is suggested to be multifactorial related to immune 
system activation. Increased cytokine release, platelet 
activation, and activated pro-oxidation cascade are thought 
to be some of the determiner of both inflammation and 
oxidative stress in CKD.
 To partially examine some the contribution of the 
immune system activation and pro-oxidative states, we 
measured CBC parameters and non-fasting cholesterol 
profiles which related to the aforementioned mechanism 
and performed correlation tests with CRP, as marker of 
inflammation and MDA, as marker of oxidative stress. 
Our results showed that in the HD group, total cholesterol/
HDL-C ratio was strongly associated with CRP and MDA. 
Combination between monocyte or neutrophil or platelet and 
HDL-C (monocyte/HDL-C ratio), neutrophil/HDL-C ratio, 
and platelet/HDL-C ratio) were also strongly associated with 
hs-CRP and MDA. These results showed the potential of 
combination of CBC parameters and non-fasting cholesterol 
profile to describe inflammation and oxidative stress in CKD 
patients receiving routine hemodialysis therapy. However, 
in the non-HD group, combination of these parameters only 
showed weak or moderate association with hs-CRP and 
MDA.
 The association of platelet/HDL-C ratio with 
inflammation and oxidative stress might stem from the 
platelet activation which is common in CKD. The platelet 
activation is one among the key factors in atherosclerotic 
formation. In the initial stage of atherosclerotic formation, 
activated platelet aggregate in the vascular endothelia and 
attract HDL-deficient monocytes (25). The accumulated 
monocytes and phospholipids in the vascular wall then 
transform into plaques that ignite further inflammatory 
response.(25) 
 The association of monocyte/ or neutrophil/HDL-C 
ratio with inflammation and oxidative stress marker 
might be explained by the fact that both monocyte and 
neutrophil are highly involved in the initiation of immune 
response. The differentiated monocytes are carried Toll-like 
receptors (TLRs) and scavenger receptors which recognize 
pathogen-associated molecular patterns (PAMPs) to remove 
microorganisms, lipids, and dying cells via phagocytosis. 
Subsequently, these cells produce cytokines as well as 
superoxide that attract more immunocompetent cells such 
as neutrophils to the sites of inflammation.(26) Together, 
the monocytes and neutrophils produce more cytokines 
including hs-CRP, interleukin (IL)-6, and interferon (IFN)-g 
that reinforce the inflammation in CKD patients (26). 
 On the other hand, dysregulation of HDL synthesis 
and degradation is prevalent in CKD patients. Normal 
HDL carries anti-oxidant and anti-inflammatory properties 
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Conclusion
Some CBC parameters and non-fasting cholesterol profile 
such as cholesterol/HDL-C, monocyte/HDL-C, neutrophil/
HDL-C and platelet/HDL-C ratio were strongly associated 
with the level of hs-CRP and MDA. Further study with 
higher number of subjects is needed to assess whether this 
parameter represent prognostic value among CKD patients.
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